Reported about 18 hours ago
Jazz Pharmaceuticals has received conditional marketing authorization from the European Commission for its bispecific antibody Ziihera (zanidatamab) to treat advanced biliary tract cancer in adults who have previously undergone systemic therapy. This approval applies to all EU member states and is based on Phase IIb clinical trial data. Further confirmation of clinical benefits is awaited from an ongoing Phase III trial.
Source: YAHOO